| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Wolfgang Probst CEO | CNSX Exchange | - ISIN |
| Canada Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
BioNxt Solutions Inc. is a prominent bioscience entity with operations across Germany, Switzerland, Austria, Israel, the United States, and Canada. Initially known as XPhyto Therapeutics Corp., the company rebranded to BioNxt Solutions Inc. in November 2022. Since its incorporation in 2017, the company has been pioneering in the development of advanced drug delivery systems and diagnostic solutions. It is headquartered in Vancouver, Canada, illustrating its global reach and commitment to innovating in the healthcare sector.
Specializing in groundbreaking drug delivery vehicles, BioNxt Solutions Inc. has developed transdermal patches and oral dissolvable films. These innovative products are primarily aimed at enhancing the delivery efficiency of neurological medications, as well as psychedelic medicine for the treatment of mental health disorders such as depression, anxiety, addiction, and trauma-related stress disorders.
The company also ventures into the development of cutting-edge diagnostic solutions. This includes rapid diagnostic tests and biosensor screening tests tailored for the early detection of diseases. By facilitating early diagnosis, these products contribute significantly towards better treatment outcomes and improved disease management. BioNxt Solutions Inc. has expanded its diagnostic portfolio to include a COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and oral biosensors for detecting H1N1 (swine flu) and H5N1 (avian flu).
Beyond product development, BioNxt Solutions Inc. offers comprehensive analytical testing and consulting services. This aspect of the business supports clients across the healthcare industry in ensuring product safety, efficacy, and compliance with regulatory standards. Such services underscore the company's versatile expertise and commitment to supporting the broader healthcare ecosystem.
Highlighting its innovation in diagnostic technology, the company develops screening tests for pathogen detections and oral health. These developments underscore BioNxt Solutions Inc.'s dedication to enhancing diagnostic accuracy and the overall health and well-being of patients globally.
Engaging in one of the most forward-looking areas of medical science, BioNxt Solutions Inc. is also involved in the production and formulation of psychedelic pharmaceuticals. This venture represents a significant leap towards developing novel treatments for mental health conditions, showcasing the company’s pioneering role in leveraging psychedelic science for therapeutic purposes.